Your browser is no longer supported. Please, upgrade your browser.
PRGO Perrigo Company Public Limited Company monthly Stock Chart
Perrigo Company Public Limited Company
IndexS&P 500 P/E128.05 EPS (ttm)1.50 Insider Own0.10% Shs Outstand146.26M Perf Week2.67%
Market Cap28.09B Forward P/E21.56 EPS next Y8.91 Insider Trans-9.00% Shs Float145.59M Perf Month0.80%
Income203.40M PEG9.33 EPS next Q2.00 Inst Own82.80% Short Float1.10% Perf Quarter3.11%
Sales4.22B P/S6.66 EPS this Y-62.00% Inst Trans11.45% Short Ratio1.21 Perf Half Y23.29%
Book/sh68.08 P/B2.82 EPS next Y16.26% ROA2.00% Target Price204.40 Perf Year25.20%
Cash/sh23.60 P/C8.14 EPS next 5Y13.72% ROE3.30% 52W Range134.71 - 215.59 Perf YTD15.07%
Dividend0.50 P/FCF33.59 EPS past 5Y3.10% ROI2.80% 52W High-10.91% Beta0.32
Dividend %0.26% Quick Ratio3.50 Sales past 5Y15.20% Gross Margin35.60% 52W Low42.58% ATR4.57
Employees10220 Current Ratio4.00 Sales Q/Q4.50% Oper. Margin17.40% RSI (14)58.62 Volatility2.72% 2.22%
OptionableYes Debt/Eq0.49 EPS Q/Q-286.10% Profit Margin7.10% Rel Volume1.93 Prev Close193.60
ShortableYes LT Debt/Eq0.46 EarningsAug 13 BMO Payout19.60% Avg Volume1.33M Price192.07
Recom2.40 SMA203.52% SMA501.60% SMA20012.49% Volume2,572,838 Change-0.79%
Jun-03-15Reiterated B. Riley & Co. Neutral $195 → $216
Apr-27-15Downgrade B. Riley & Co. Buy → Neutral
Apr-22-15Reiterated B. Riley & Co. Buy $189 → $195
Apr-10-15Downgrade Argus Buy → Hold
Feb-06-15Reiterated RBC Capital Mkts Outperform $177 → $175
Nov-12-14Reiterated Argus Buy $160 → $175
Nov-07-14Reiterated RBC Capital Mkts Outperform $169 → $177
Sep-22-14Reiterated RBC Capital Mkts Outperform $160 → $169
May-15-14Reiterated Argus Buy $175 → $160
May-08-14Reiterated B. Riley & Co. Neutral $170 → $157
May-08-14Downgrade RBC Capital Mkts Top Pick → Outperform $187 → $160
Mar-03-14Reiterated UBS Buy $176 → $190
Mar-03-14Reiterated Stifel Buy $165 → $175
Feb-25-14Reiterated CRT Capital Buy $165 → $175
Feb-07-14Downgrade B. Riley & Co. Buy → Neutral
Jan-16-14Reiterated Argus Buy $160 → $175
Jan-07-14Initiated RBC Capital Mkts Top Pick $187
Dec-12-13Reiterated Stifel Buy $150 → $165
Nov-07-13Reiterated Argus Buy $152 → $160
Nov-04-13Reiterated UBS Buy $140 → $160
Jul-28-15 03:00PM  What to Expect from Exelixis (EXEL) This Earnings Season? - Analyst Blog
01:10PM  There's 'Life After Teva' For Mylan, Says Leerink at
09:44AM  Faber Report: Mylan continues fight for Perrigo
Jul-27-15 06:12PM  Mylan independence from Teva's embrace comes with a price
05:22PM  Teva Tags Allergan's Generics: $40.5 Bil
04:45PM  Mylan to gather shareholders Aug. 28 in Amsterdam to decide Perrigo bid at
04:43PM  Analysts expect more tie-ups in generic drug business
03:58PM  Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders PR Newswire
03:48PM  Mylan must raise its bid for Perrigo
03:18PM  With Teva out of the way, Mylan clear to focus on Perrigo deal at
03:14PM  Allergan to own 10% stake in Teva
12:54PM  The $100 Billion Deal Is Still Out There for Pharma: Real M&A at Bloomberg
12:42PM  Trending Now: PRGO
12:11PM  Why Mylan N.V. Stock Slumped Today at Motley Fool
12:08PM  Teva Buys Allergan Unit: How Mylan, Other Biotech Stocks Are Reacting
11:30AM  Teva deal pushes Allergan up, Mylan down; GrubHub downgraded
10:51AM  Teva Drops Mylan Chase To Buy Allergan Generics Unit at Investor's Business Daily
09:09AM  Mylan Shares Plummet as Teva Abandons Takeover for Allergan Deal at Bloomberg
09:09AM  Mylan Shares Plummet After Teva Abandons Takeover for Allergan Deal
07:48AM  Early movers: AGN, MYL, MHFI, UBS, FCAU & more at CNBC
07:35AM  Teva ends hostile bid for Mylan at
07:16AM  Israeli drug firm Teva buys Allergans generics business for $40 billion at Fortune
07:00AM  Pharmaceuticals continue to consolidate
Jul-24-15 08:02AM  Perrigo Company plc To Release Second Quarter Calendar Year 2015 Results On August 5, 2015 PR Newswire
01:39AM  Drugmaker Mylan Uses Dutch Foundation to Fend Off Hostile Bid at The Wall Street Journal
Jul-23-15 07:08PM  Mylan foundation tries to block Teva takeover bid with poison pill Reuters
03:50PM  Perrigo (PRGO) to Buy Yokebe Brand; Boost EU Presence - Analyst Blog
02:57PM  Mylan's Stichting: Will It Work? at
01:31PM  Mylan puts up barrier to Teva with Dutch legal maneuver
11:35AM  Mylan: It's Stichting Time at The Wall Street Journal
09:44AM  Faber Report: Mylan, Teva tug of war
Jul-22-15 07:11AM  Perrigo To Acquire Leading German Dietary Supplement Brand Yokebe PR Newswire
Jul-20-15 01:31PM  Wedgewood Partners Investor Letter Dishes On QUALCOMM Inc (QCOM), Perrigo Company (PRGO), More at Insider Monkey
Jul-17-15 09:20AM  LH supports Visium Asset Management. PRGO Drags
Jul-14-15 03:15PM  Mylan has another ally in its battle against Teva takeover at
Jul-10-15 04:06PM  Dealpolitik: Why Mylan Has a Leg Up in the Vote on Its Perrigo Bid at The Wall Street Journal
Jul-08-15 10:44AM  Evaluating Teva, With and Without a Mylan Deal at The Wall Street Journal
Jul-07-15 04:20PM  Rumor Has it that Teva Will Raise Mylan Bid to $25 Billion - Analyst Blog
Jul-06-15 05:06PM  Teva Plans to Raise Mylan Bid to $86-$88/Share This Week
03:14PM  Teva prepares to raise its bid for Mylan at Financial Times
12:17PM  Teva Said Planning to Raise Mylan Bid to $86-$88/Share This Week at Bloomberg
07:17AM  Teva to lift bid for Mylan: report AFP
Jul-02-15 04:50PM  [video]Mergers and Acquisitions Boom Will Keep Rolling as Interest Rates Rise at TheStreet
Jul-01-15 02:34PM  History Tells Jacob Gottlieb His Top 3 Large-Cap Positions Beat The Market at Insider Monkey
01:13PM  Top Takeaways From BMO's Specialty Pharma Day
Jun-30-15 11:48AM  A New Rider in the Perrigo, Mylan, Teva Merger Merry-Go-Round at
Jun-29-15 06:37PM  Boehringer's Roxane Labs draws bid from Hikma, Mallinckrodt- Bloomberg
Jun-25-15 12:00PM  EU regulators to rule on Mylan bid for Perrigo by July 29 Reuters
Jun-24-15 09:07AM  Mylan eyes Tel Aviv listing if Perrigo deal goes ahead Reuters
03:07AM  Edited Transcript of PRGO presentation 23-Jun-15 3:45pm GMT
Jun-23-15 12:10PM  Perrigo Going Up With Or Without Mylan, Says BMO at Investor's Business Daily
08:16AM  Mylan CFO to meet Tel Aviv bourse chief to discuss listing - source Reuters
Jun-22-15 01:30PM  Teva Announces Acquisition of 4.61% Interest in Mylan - Analyst Blog
Jun-19-15 09:30AM  Teva gains standing to challenge Mylan poison pill at
09:07AM  Teva takes 4.6 percent stake in Mylan as part of bid
08:53AM  Teva Takes 4.6% Stake in Mylan at The Wall Street Journal
Jun-18-15 05:20PM  Teva ups Mylan stake, handed setback in court ruling at
03:16PM  Teva Bid for Mylan Could Be 'Imminent' at
Jun-17-15 04:50PM  Mylan Inks Deal with Pulmatrix for Respiratory Disease Drug - Analyst Blog
12:17PM  Volatility Marks the Day for US Markets on June 16
12:49AM  Edited Transcript of PRGO presentation 12-May-15 8:00pm GMT
Jun-16-15 08:01PM  Abbott Backs Mylan and Its Strategy to Buy Perrigo at TheStreet
07:52PM  Business Watch at The Wall Street Journal
05:06PM  Stocks End Near Highs; Perrigo Rebounds On Mylan Deal at Investor's Business Daily
04:59PM  Adobe shares slide after hours on weak outlook at MarketWatch
03:39PM  Teva's Auspex Buyout Pays, But Mylan Bid Hits Snag at Investor's Business Daily
11:25AM  Mylan's largest shareholder Abbott Laboratories backs in Perrigo bid at
10:11AM  Abbott to Vote in Favor of Mylan's Perrigo Deal at The Wall Street Journal
09:20AM  Abbott to vote for Mylan's acquisition of Perrigo
09:19AM  Mylan Issues Statement in Response to Abbott's Support for Perrigo Transaction PR Newswire
09:17AM  Abbott Will Back Mylans Perrigo Bid Using 14.5% Share Stake at Bloomberg
Jun-10-15 06:14PM  Aberdeen Fund Manager Sees Israeli Stocks Pushed by Strong Economy at TheStreet
Jun-08-15 02:30PM  Teva again increases share in Mylan N.V. at
01:07PM  Teva accuses Mylan of 'desperate attempt' to suppress bid
12:15PM  Teva fires back at Mylan chairmans criticism of proposed takeover at
Jun-03-15 03:32PM  Perrigo to Buy OTC Brands from GlaxoSmithKline in Europe - Analyst Blog
Jun-02-15 05:37PM  Dealpolitik: Hand-to-Hand Combat as Teva/Mylan Showdown Approaches at The Wall Street Journal
04:45PM  Perrigo Buys GlaxoSmithKline, Novartis Consumer Medicines at TheStreet
01:59PM  Perrigo Plays European Defense at The Wall Street Journal
01:08PM  Will Perrigo's Glaxo Buy Make It Too Pricey? at Investor's Business Daily
10:00AM  Perrigo expands its drug portfolio
09:41AM  Faber Report: Mylan sends letter to Teva
08:45AM  Five things to know today, and Perrigo doesn't sound like a company that thinks it'll be acquired at
07:48AM  Early movers: MDT, PVH, DG, SHLD, AAPL & more at CNBC
07:00AM  Actavis And Perrigo Receive FDA Approval Of Guaifenesin/Pseudoephedrine, The Store Brand Equivalent To Mucinex┬« D Tablets PR Newswire
06:27AM  Perrigo To Acquire Portfolio Of Leading OTC Brands From GSK PR Newswire
Jun-01-15 06:39PM  Mylan tells Teva to 'stop playing games' at Financial Times
04:40PM  Mylan executive chairman tells Teva to stop meddling in its affairs at
08:20AM  3 Specialty Pharma Stocks That Could Be Acquired in 2015 at 24/7 Wall St.
May-29-15 05:31PM  Actavis PLC (ACT), Laboratory Corp. of America Holdings (LH) Among Health Fund Visiums Top Picks at Insider Monkey
12:25PM  Teva buying up shares of Mylan at
May-27-15 04:13PM  Perrigo Company To Present At The Jefferies 2015 Healthcare Conference PR Newswire
May-26-15 12:20PM  Exclusive: Mylan chairman says Teva offers nothing we can't do on our own at
08:05AM  Five things to know today, and why Mylan NV didn't take a holiday at
May-25-15 09:47AM  Mylan/Perrigo Clarification PR Newswire
08:02AM  Considering the Investment Impact of Baby Boomers Retirement
May-21-15 04:02PM  Energy Stocks Dominating Billionaire Izzy Englanders Top Holdings: NextEra Energy Inc (NEE), Noble Energy, Inc. (NBL), Devon Energy Corp (DVN) at Insider Monkey
May-20-15 09:29AM  10 S&P 500 Companies to Have the Most Revenue Growth in 2015 at TheStreet
May-19-15 07:31PM  Mariko Gordon Sells Lumber Liquidators, Western Digital
08:19AM  Five things to know today, and a big golden parachute in Heinz merger at
Perrigo Company plc, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Its Consumer Healthcare segment offers OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, and animal health products, as well as in the areas of feminine hygiene, diabetes care, and dermatological care; and contract manufacturing services. The company's Nutritionals segment offers infant and toddler formula products, infant and toddler foods, as well as vitamins, minerals, and dietary supplement products to retailers, distributors, and consumers. Its Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of Rx drugs in topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, and powders, as well as controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. This segment provides its products to chain drug stores, wholesalers, distributors, hospital systems, and group purchasing organizations. The company's API segment develops, manufactures, and markets API that are used in the production of pharmaceutical products to generic drug industries and branded pharmaceutical companies. Its Specialty Sciences segment provides Tysabri, which is used for the treatment of Multiple Sclerosis; and Prialt, a non-narcotic intrathecal analgesic. The company also offers pharmaceutical and medical diagnostic products. The company offers its products primarily in the United States, the United Kingdom, Mexico, Israel, and Australia, as well as in Canada, China, and Latin America. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KINGMA TODD WExecutive VP, General CounselApr 29Option Exercise58.821,70099,99411,064May 01 04:19 PM
KINGMA TODD WExecutive VP, General CounselApr 29Sale190.271,700323,4599,364May 01 04:19 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyApr 14Option Exercise107.058,800941,9974,148Apr 16 04:14 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyApr 14Sale200.278,8001,762,3760Apr 16 04:14 PM
KINGMA TODD WExecutive VP, General CounselApr 13Option Exercise35.851,30046,60510,664Apr 15 02:57 PM
KINGMA TODD WExecutive VP, General CounselApr 13Sale198.441,300257,9729,364Apr 15 02:57 PM
Shah JatinSr VP & Chief Scientific OfficMar 13Sale165.502,000331,0003,291Mar 17 10:50 AM
Yu LouisExecutive VP Global QualityMar 12Sale166.2714023,2784,746Mar 16 04:35 PM
Farrington ThomasSenior VP and CIOFeb 20Sale151.1851778,161321Feb 24 04:26 PM
Farrington ThomasSenior VP and CIOFeb 06Option Exercise0.0079801,119Feb 09 04:37 PM
MORRIS HERMAN JRDirectorNov 14Sale154.4220030,8831,400Nov 17 05:22 PM
Kochan SharonEVP, GM InternationalNov 10Option Exercise90.655,367486,51910,767Nov 12 04:37 PM
Kochan SharonEVP, GM InternationalNov 10Sale156.365,367839,1845,400Nov 12 04:37 PM
Yu LouisExecutive VP Global QualityNov 10Sale155.1125940,1734,886Nov 12 04:33 PM
Brown Judy LExecutive VP & CFONov 03Option Exercise48.923,515171,9539,445Nov 05 04:39 PM
Brown Judy LExecutive VP & CFONov 03Sale160.603,515564,5077,445Nov 05 04:39 PM
Brown Judy LExecutive VP & CFOOct 01Option Exercise48.923,515171,9539,445Oct 02 04:26 PM
Brown Judy LExecutive VP & CFOOct 01Sale150.723,515529,7817,445Oct 02 04:26 PM
Kochan SharonEVP, GM InternationalSep 03Sale150.001,116167,4005,400Sep 04 04:42 PM
KINGMA TODD WExecutive VP, General CounselSep 03Sale150.101,000150,0952,000Sep 03 05:00 PM
Farrington ThomasSenior VP and CIOSep 02Sale150.361,741261,773321Sep 03 05:12 PM
KINGMA TODD WExecutive VP, General CounselAug 29Option Exercise35.851,25044,81310,614Sep 03 05:00 PM
KINGMA TODD WExecutive VP, General CounselAug 29Sale149.301,250186,6259,364Sep 03 05:00 PM